Key Takeaways AZN's oncology sales hit $5.6B in Q1 2025, up 13%, led by drugs like Tagrisso, Imfinzi, and Enhertu. Truqap and Datroway launches in HR HER2- breast cancer show early sales strength and FDA momentum. AZN eyes pipeline growth with late-stage drugs camizestrant and volrustomig across multiple cancer types.AstraZeneca (AZN) is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generat ...

Key Takeaways SMMT surged after reports of AstraZeneca exploring a $15 billion licensing deal for ivonescimab. The deal may include billions upfront, with milestone payments tied to Ivonescimab's progress. Ivonescimab showed superiority over Keytruda and Tevimbra in late-stage NSCLC trials.Shares of clinical-stage company Summit Therapeutics (SMMT) rose nearly 9% on Thursday following a report issued by Bloomberg, which stated that pharma giant AstraZeneca (AZN) is in discussions with the company for a po ...

Key Takeaways AstraZeneca gained EU approval for Imfinzi to treat muscle-invasive bladder cancer in adults. Imfinzi showed a 32% reduced risk of disease progression or death in the NIAGARA phase III study. Imfinzi sales rose 16% in Q1 2025 to $1.26B, driven by lung and liver cancer treatment demand.AstraZeneca (AZN) announced that the European Commission has approved its blockbuster cancer drug, Imfinzi (durvalumab), for a bladder cancer indication in the European Union (EU).The regulatory body in Europe ...

Key Takeaways MRK's phase III pipeline has nearly tripled since 2021, boosted by in-house growth and M&A deals. MRK plans around 20 new drug and vaccine launches, many with blockbuster potential, over the next few years. Capvaxive and Winrevair have shown strong launches, supporting growth as Keytruda's patent expiration nears.Merck (MRK) has built a substantial portfolio of new products and pipeline candidates in areas like oncology, vaccines, neuroscience, and infectious disease.Merck’s phase III pipeli ...

Core Insights - AbbVie has established a significant oncology franchise, expanding from blood cancer drugs to include therapies for solid tumors, with five oncology products now available [1][7] - The oncology segment contributed over 12% to AbbVie's total revenues in Q1 2025, with expectations for Emrelis, its first internally developed lung cancer drug, to start contributing in Q3 2025 [1][2][7] Company Strategy - AbbVie is pursuing both organic and inorganic growth strategies, with recent additions to its oncology portfolio coming from acquisitions and collaborations, while Emrelis represents an internal development [2] - The company has a diverse pipeline of promising therapies, including etentamig for multiple myeloma and Temab-A for colorectal and gastroesophageal cancers, indicating a strong focus on expanding its oncology offerings [3][7] Competitive Landscape - Major competitors in the oncology space include AstraZeneca, Merck, and Pfizer, with AstraZeneca's oncology sales accounting for nearly 41% of its total revenues and growing by 13% in Q1 2025 [4] - Merck's Keytruda accounted for over 46% of its total revenues in Q1 2025, while Pfizer's oncology revenues grew by 7%, making up over 27% of its total revenues [5] Financial Performance - AbbVie shares have outperformed the industry year to date, although the company's valuation is not considered cheap, trading at a P/E ratio of 13.99 compared to the industry average of 14.81 [6][9] - The Zacks Consensus Estimate for AbbVie's earnings has increased for both 2025 and 2026, indicating positive market sentiment [10]

Key Takeaways PFE's non-COVID revenues are rising, fueled by new drugs, key in-line products and Seagen acquisition. The Seagen deal added four ADCs to PFE's oncology portfolio, boosting revenues in 2024 and early 2025. PFE shares trade at a forward P/E of 7.97, well below the industry average and its 5-year historical mean.With the end of the pandemic, sales of Pfizer’s (PFE) COVID products, Comirnaty and Paxlovid, have declined. Though COVID revenues are declining, Pfizer’s non-COVID operational revenue ...

本文节选自彭博终端。如您还不是终端用户，您可在文末" 阅读原文 "联系我们预约产品演示。 彭博行业研究 2025 ASCO年会报告 近期，2025年美国临床肿瘤学会（ASCO）年会在美国芝加哥举办。阿斯利康连续第七年成为 大会领头羊，展示了对实践具有变革意义的数据，有望助力其在 2030 年实现 800 亿美元销售 额的目标。今年的重点主要集中在胃癌领域：英飞凡（Imfinzi）的 MATTERHORN 研究凭借 前所未有的无事件生存期（EFS）优势，打开了一个 20 亿美元的市场；以及乳腺癌领域：优 赫得（Enhertu）在一线 HER2 阳性乳腺癌的 DESTINY-Breast09 试验中再次发力。 包括TIGIT和KRAS在内的多种肺癌数据集正在新的利基领域取得进展，而在其他领域，辉瑞 的Braftovi使结直肠癌患者的总生存期（OS）增加了一倍。在经历了20年的停滞之后，Bristol Myers的Opdivo和默克的Keytruda终于在头颈癌领域取得了进展。 长按或扫描二维码 阅读完整报告 * 本报告语言为英文。 凭借KEYNOTE-585试验，阿斯利康抓住了默克公司在胃癌围手术期中错失的机会。 ...

点击蓝字，关注我们 今日上午港股 1.蜜雪集团 (02097) 涨超 7%，创新高。 大和上调其目标价至608港元，看好同店销售增长及开店速度。 2.连连数字 (02598) 涨近 10%。 香港《稳定币条例》正式刊宪生效。 3.汽车股集体下跌。理想汽车-W、长城汽车、广汽集团均跌超2%。 消息面上，工信部、中汽协发声反 对"内卷式"价格战。机构（海通国际）指价格战催化行业洗牌，动销波动加剧。 4.石四药集团 (02005) 跌超 7%。 公司公布一季度业绩， 营业额同比降36.9% ，股东应占溢利同比降 59.5%。预期上半年溢利同比下降45%-60%，主因需求回落、集采及竞争加剧带来的价格压力。 5.光伏股全线走低。新特能源、信义能源、福莱特玻璃、信义光能均跌超4%。 消息面上，4月光伏抢装 潮后，5月预期中的"531"抢装潮未现。 6.内房股早盘集体走低。富力地产、融创中国、新城发展、雅居乐集团均跌超4%。 消息面上，中指研究 院数据显示1-5月百强房企销售额同比降10.8%，5月单月同比降17.3%（降幅扩大）。 7.重庆农村商业银行 (03618) 涨近 5%。 消息面上，公司首次被纳入沪深300指 ...

Core Insights - AstraZeneca's Imfinzi receives positive recommendation from the European Medicines Agency for bladder cancer treatment [1][2][3] - The recommendation is based on the phase III NIAGARA study, showing a 32% reduction in disease progression risk [3] - Imfinzi is already approved in the U.S. for a similar indication, marking a significant advancement in immunotherapy for muscle-invasive bladder cancer [4] Regulatory Developments - Imfinzi is recommended for use in combination with gemcitabine and cisplatin as a neoadjuvant treatment for muscle-invasive bladder cancer [2] - Regulatory applications for Imfinzi in bladder cancer are under review in Japan and other countries [8] Financial Performance - AstraZeneca's stock has increased by 7.5% year-to-date, contrasting with a 5.7% decline in the industry [5] - Imfinzi generated sales of $1.26 billion in Q1 2025, reflecting a 16% increase driven by demand in lung and liver cancer indications [10] Ongoing Research - Additional studies are underway for Imfinzi targeting other cancer indications, reinforcing its role as a key revenue driver for AstraZeneca's oncology portfolio [10] - The phase III POTOMAC study demonstrated significant improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer patients [9]

AstraZeneca (AZN) stock has declined 6.4% in the past three months.Although AstraZeneca faces its share of challenges, a significant portion of this price decline is attributed to broader market uncertainties and a volatile macroeconomic environment.The sky-high tariffs imposed by the United States and retaliatory tariffs by China and some other countries hurt global stock markets. Though the massive tariffs imposed by the United States and China are now on a pause, it is only a temporary suspension, and no ...